Skip to content
value.today

Cime Therapeutics Inc.

🇺🇸 Denver, Colorado, USABiotechnologyFounded 2024
Total raised
$2 M
1 round on record
Latest round
$2 M
Mar 2025
First round on record
Mar 2025
Today
Private
No later event on record

Funding rounds

1 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Cime Therapeutics Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Mar 2025$2 MNo. 1$2 to $10 million

Cime Therapeutics Inc.: Raise no. 1, Mar 2025

Investors in this round

3 investors had bought by the notice of Mar 21, 2025: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $3 M offered; $0 M still to sell
Smallest investment taken
no minimum stated
What was sold
options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
$80,000 (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • James Thomas Brewster II · Executive Officer, Director
  • Chris Thomas Erickson · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by James Thomas Brewster II, Chief Executive Officer. Source: SEC Form D, newest notice filed Mar 21, 2025. Read the notice at the SEC.

optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Cime Therapeutics Inc. chose not to state its revenue in its newest notice of a funding round (Mar 2025).

    SEC Form D · Mar 2025

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Mar 2025

That is all the official record says: Cime Therapeutics Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Cime Therapeutics Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 3 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Cime Therapeutics Inc.
NameRoleNamed in
James Thomas Brewster IIExecutive officerMar 2025
Chris Thomas EricksonDirectorMar 2025
James Thomas Brewster IIDirectorMar 2025